WO2005051952A1 - アデニン誘導体の製造方法 - Google Patents
アデニン誘導体の製造方法 Download PDFInfo
- Publication number
- WO2005051952A1 WO2005051952A1 PCT/JP2004/017435 JP2004017435W WO2005051952A1 WO 2005051952 A1 WO2005051952 A1 WO 2005051952A1 JP 2004017435 W JP2004017435 W JP 2004017435W WO 2005051952 A1 WO2005051952 A1 WO 2005051952A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- carbon atoms
- alkyl group
- producing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Definitions
- the present invention relates to a method for producing an adenine derivative which is useful as an intermediate for producing pharmaceuticals and agricultural chemicals.
- adenine derivative is useful as an intermediate for producing nucleic acids, drugs, agricultural chemicals, and the like.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 20 carbon atoms which may have a substituent.
- Japanese Patent Application Laid-Open No. 2002-155082 proposes a method in which a 4 (5) -amino-5 (4) -cyanoimidazole derivative is reacted with an amide compound and a halogenating agent. I have.
- the method described in this document is not preferable as an industrial production method because, for example, when phosphorus oxychloride or the like is used as a halogenating agent, the post-treatment becomes complicated.
- the present invention has been made in view of such circumstances, and it is an object of the present invention to provide a method for industrially and advantageously producing an adenine derivative represented by the formula (II) in a high yield.
- R 1 represents a hydrogen atom or an alkyl group having 1 to 20 carbon atoms which may have a substituent.
- a phenyl group which may be represented by the formula (II):
- the production method of the present invention is preferably a method for producing a compound in the above formula (II), wherein the substituent R 1 is an alkyl group having 1 to 5 carbon atoms replaced by a hydroxyl group. More preferably, it produces a compound wherein 1 is a 2-hydroxypropyl group.
- ammonium chloride as the ammonium salt.
- R 1 represents a hydrogen atom or an optionally substituted carbon number of 1 to 20. Represents an alkyl group.
- alkyl group having 1 to 20 carbon atoms which may have a substituent include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group, —Butyl group, isobutyl group, n-pentyl group, n-hexyl group, n-heptyl group, n-octyl group, n-decyl group, n-undecyl group, n-dodecyl group and the like.
- the substituent of the alkyl group having 1 to 20 carbon atoms is not particularly limited as long as it is inert to the reaction in the production method of the present invention.
- Alkylsulfonyl groups such as methylsulfonyl group and ethylsulfonyl group
- phenylsulfonyl groups which may have a substituent such as phenylsulfonyl group and 4-methylphenylsulfonyl group
- methoxycarponyl Group an alkoxyl group such as an ethoxycarbonyl group; and the like.
- R 1 is preferably an alkyl group having 1 to 5 carbon atoms and substituted with a hydroxyl group.
- alkyl group having 1 to 5 carbon atoms substituted with a hydroxyl group include a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, a 1,1-dimethyl-2-hydroxyethyl group , 1-hydroxypropyl group, 2-hydroxypropyl group, 3-hydroxypropyl group, 1-hydroxy-2-methylpropyl group, 2-hydroxy-2-methylpropyl group, 3-hydroxy-12-methylpropyl group, 1-hydroxy Butyl, 1-methyl-2-hydroxyethyl, 1-hydroxybutyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 1-hydroxypentyl, 2-hydroxypentyl, 3- Monohydroxy-substituted carbon such as hydroxypentyl, 4-hydroxypentyl, and 5-hydroxypentyl An alkyl group having a prime number of 1 to 5;
- Dihydroxymethyl group 1,2-dihydroxyethyl group, 2,2-dihydroxyethyl group, 1,1-dihydroxypropyl group, 2,2-dihydroxypropyl group, 1,2-dihydroxypropyl group, 1,3 —Dihydroxypropyl group, 2,3-dihydroxypropyl group, 1,2-dihydroxybutyl group, 1,3-dihydroxybutyl group, 1,4-dihydroxybutyl group, 2,3-dihydroxybutyl group, 3,4-dihydroxy Butyl group, 1,2-dihydroxypentyl group, 2,3-dihydroxypentyl group, 3,4-dihydroxypentyl group, 4,5-dihydroxypentyl group, 2,5-dihydroxypentyl group, 3,4-dihydroxy And dihydroxy-substituted alkyl groups having 1 to 5 carbon atoms, such as an ethyl group and a 1,5-dihydroxypentyl group.
- a monohydroxyl group-substituted alkyl group having 1 to 5 carbon atoms is more preferable, and a 2-hydroxypropyl group is particularly preferable.
- R 1 When R 1 is an alkyl group having 1 to 5 carbon atoms substituted with a hydroxyl group, R 1 may have an asymmetric carbon atom. In this case, R 1 may be an optically active group or a non-optically active group (racemic). In the production method of the present invention, even when R 1 is an optically active group, the reaction proceeds in a state where the stereo is maintained.
- R 2 represents a hydrogen atom, an alkyl group having 1 to 10 carbon atoms which may have a substituent, or a phenyl group which may have a substituent.
- alkyl group having 1 to 10 carbon atoms of the alkyl group having 1 to 10 carbon atoms which may have a substituent include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, and an n-butyl group. And sec-butyl, t-butyl, isobutyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-decyl and the like.
- the substituent is not particularly limited as long as it is an inactive group in the reaction of the present invention. However, an electron-withdrawing group such as an octylogen atom is preferable because the desired product can be obtained in high yield.
- amide compounds are known substances and can be produced by known methods. Also, commercially available products can be used as they are.
- the amount of the amide compound used can be used without any limitation as long as stirring can be easily performed in the reaction. Whether or not stirring can be facilitated depends on the type of R 1 and the type of ammonium salt of the compound represented by the formula (I).
- the usual amount is 0.5 to 10 liters, preferably 0.8 to 1.2 liters, per mole of the compound represented by the formula (I).
- the production method of the present invention uses an ammonium salt.
- the ammonium salt used in the present invention is not particularly limited.
- ammonium salts of inorganic acids such as ammonium chloride, ammonium bromide, ammonium iodide, ammonium sulfate, ammonium nitrate, and ammonium phosphate
- aliphatic carboxylic acids such as ammonium acetate, ammonium propionate, and ammonium stearate.
- ammonium salt of an aromatic carboxylic acid such as ammonium benzoate
- an ammonium salt of a hydroxycarboxylic acid such as ammonium lactate or ammonium salicylate
- ammonium salt an ammonium salt of an inorganic acid or an ammonium salt of an aliphatic carboxylic acid is preferable, and ammonium acetate or ammonium chloride is more preferable.
- ammonium chloride is particularly preferred.
- the amount of the ammonium salt used is usually 1 to 100 times, preferably 2 to 10 times, more preferably 2 to 5 times the mole of the compound represented by the formula (I). is there.
- the present invention is carried out by adding a predetermined amount of the compound represented by the formula (I), the amide compound and the ammonium salt to a suitable reaction solvent, and stirring the resulting mixture at a predetermined temperature for a predetermined time.
- the reaction solvent to be used is not particularly limited as long as it is inert, and any solvent which can be generally used industrially can be used.
- hydrocarbon solvents such as benzene, toluene, xylene, and cyclohexane
- halogen solvents such as chloroform, methylene chloride, cyclobenzene, and dichlorobenzene
- getyl ether, dioxane, Ether solvents such as tetrahydrofuran, diethylene glycol and dimethyl ether; and the like.
- These can be used alone or as a mixed solvent of two or more.
- the amount of the reaction solvent used is not particularly limited.
- the amount of the reaction solvent to be used is generally 0.1 to 10 liters, preferably 0.3 to 2 liters, per 1 mol of the compound represented by the formula (I).
- the amide compound can be used as a solvent in a large excess.
- formamide when used as the amide compound, it is preferable to use an excess amount of formamide and also serve as a solvent.
- formamide when used, it is used in an amount of usually 0.5 to 10 liters, preferably 0.8 to 1.2 liters, per 1 mol of the compound represented by the formula (I).
- the reaction temperature is usually 100 to 200 ° C, preferably 120 to 150 ° C. In this temperature range, the target product can be industrially advantageously produced. If the reaction temperature is lower than 100 ° C., the reaction rate becomes slow. If the reaction temperature is higher than 200 ° C., by-products are formed, and post-treatment becomes difficult.
- the reaction time is usually from one hour to several tens of hours.
- the reaction can be completed within this time range.
- the reaction solution After completion of the reaction, the reaction solution is allowed to cool, and the precipitated crystals are collected by filtration to obtain the desired adenine derivative represented by the above formula (II). Further, the adenine derivative represented by the above formula (II) can be obtained in the form of a hydrochloride by charging the reaction solution into an aqueous hydrochloric acid solution.
- R 1 is an optically active group
- its optical activity is maintained, so that an intermediate for a pharmaceutical compound often requiring an optically active form is produced. It is particularly effective as a method.
- VIII 5-amino-4_cyanoimidazole (VII) 1.08 g (10 mmo 1), 2.67 g (5 Ommo 1) of ammonium chloride was added to 10 ml of formamide, and the mixture was stirred at 140 ° C. for 6.5 hours.
- reaction solution was allowed to cool to room temperature.
- the reaction solution was added to an aqueous hydrochloric acid solution containing 4 ml of 35% hydrochloric acid in 30 ml of cold water.
- the obtained solution was quantitatively analyzed by high performance liquid chromatography (HPLC). As a result, it was found that the desired adenine represented by the formula (VIII) was obtained with a reaction yield of 98.2% (corresponding to 1.33 g).
- Bu f fer 3 mM 1 sodium monooctanesulfonate + 40 M potassium dihydrogen phosphate + 85% phosphoric acid 24 mM
- an adenine derivative useful as an agro-pharmaceutical intermediate can be produced industrially and advantageously in a high yield under mild conditions.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005515778A JP4440891B2 (ja) | 2003-11-25 | 2004-11-17 | アデニン誘導体の製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003394317 | 2003-11-25 | ||
JP2003-394317 | 2003-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005051952A1 true WO2005051952A1 (ja) | 2005-06-09 |
Family
ID=34631454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/017435 WO2005051952A1 (ja) | 2003-11-25 | 2004-11-17 | アデニン誘導体の製造方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4440891B2 (ja) |
WO (1) | WO2005051952A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102321086A (zh) * | 2011-09-21 | 2012-01-18 | 杭州科本药业有限公司 | 一种腺嘌呤的合成方法 |
CN102887899A (zh) * | 2012-09-28 | 2013-01-23 | 扬州大学 | 一种新的腺嘌呤化学合成方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1134974A (en) * | 1966-06-18 | 1968-11-27 | Ajinomoto Kk | Process for preparing adenine and derivatives thereof |
JPS515000B1 (ja) * | 1970-12-09 | 1976-02-16 | ||
WO1998001448A1 (fr) * | 1996-07-03 | 1998-01-15 | Japan Energy Corporation | Nouveaux derives de purine |
JP2001213867A (ja) * | 2000-01-27 | 2001-08-07 | Daiso Co Ltd | 9−(2−ヒドロキシアルキル)プリン誘導体および1−(2−ヒドロキシアルキル)ピリミジン誘導体の製造法 |
-
2004
- 2004-11-17 WO PCT/JP2004/017435 patent/WO2005051952A1/ja active Application Filing
- 2004-11-17 JP JP2005515778A patent/JP4440891B2/ja not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1134974A (en) * | 1966-06-18 | 1968-11-27 | Ajinomoto Kk | Process for preparing adenine and derivatives thereof |
JPS515000B1 (ja) * | 1970-12-09 | 1976-02-16 | ||
WO1998001448A1 (fr) * | 1996-07-03 | 1998-01-15 | Japan Energy Corporation | Nouveaux derives de purine |
JP2001213867A (ja) * | 2000-01-27 | 2001-08-07 | Daiso Co Ltd | 9−(2−ヒドロキシアルキル)プリン誘導体および1−(2−ヒドロキシアルキル)ピリミジン誘導体の製造法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102321086A (zh) * | 2011-09-21 | 2012-01-18 | 杭州科本药业有限公司 | 一种腺嘌呤的合成方法 |
CN102887899A (zh) * | 2012-09-28 | 2013-01-23 | 扬州大学 | 一种新的腺嘌呤化学合成方法 |
Also Published As
Publication number | Publication date |
---|---|
JP4440891B2 (ja) | 2010-03-24 |
JPWO2005051952A1 (ja) | 2007-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6511346B2 (ja) | ハロゲン化環式化合物の合成方法 | |
CA1334417C (en) | Process for preparing pyridine-2,3-dicarboxylic acid compounds | |
CN111386257B (zh) | 使用新中间体制备恩杂鲁胺的方法 | |
EP1957497B1 (en) | Processes for preparing intermediates of pemetrexed | |
JP5008404B2 (ja) | メチレンジスルホネート化合物の製造方法 | |
WO2005051952A1 (ja) | アデニン誘導体の製造方法 | |
EP2141151B1 (en) | Method for producing 2-haloimidazole compound | |
JP5245408B2 (ja) | 1−置換−5−アシルイミダゾール化合物の製法 | |
JP4161367B2 (ja) | 5−置換オキサゾール化合物および5−置換イミダゾール化合物の製造方法 | |
JP3963523B2 (ja) | ジアゾ化合物の製造方法 | |
JP2879164B2 (ja) | 置換2―シアノイミダゾール系化合物の製造方法 | |
Abdel-Rahman | Synthesis of some new biologically active 2, 3-disubstituted quinazolin-4-ones | |
EP3266771B1 (en) | Synthesis of photoactivable caged cyclofen-oh and derivatives thereof | |
JPS60136572A (ja) | トリアゾロン誘導体の製造方法 | |
JP4693261B2 (ja) | 5−置換オキサゾール化合物の製造方法 | |
JP2004323379A (ja) | アミノピラゾール誘導体の製造方法 | |
JPH04139170A (ja) | 置換ピリジンスルホニルカーバメート系化合物及びその製造方法並びに置換ピリジンスルホンアミド系化合物の製造方法 | |
Abramova et al. | SYNTHESIS OF 1, 3-PROPYLENE-BIS-[4, 4'-METHYLENE-BIS-(1, 2-DIHYDRO-1, 5-DIMETHYL-2-PHENYL-3-PYRAZOLONE)] AS A NEW DERIVATIVE OF DIANTIPYRILMETHANE | |
JPH04352787A (ja) | ソルビトール誘導体 | |
JPS60120869A (ja) | アミノピラゾ−ルの製法 | |
JP2000344755A (ja) | 2−アミジノピリミジン類の製造法 | |
HU213619B (en) | Process for producing quinolinyl acetic acid esters | |
JPH08176089A (ja) | 2−置換フェニルヒドラゾノ−プロピオン酸エステル類の製造方法 | |
WO2007069290A1 (ja) | 3,7(9)-ジヒドロ-1h-プリン-2,6-ジチオン化合物の製造方法 | |
JPS59225164A (ja) | 4−ヒドロキシ−6−メチルニコチン酸の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005515778 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |